CEO Ulf Hannelius stepped down after 10 years following negative interim results from the DIAGNODE-3 Phase 3 trial on March 27, 2026.
Anders Essen-Möller appointed Executive Chairman effective April 22, 2026, with a search underway for a new CEO.
The company initiated a strategic review including partnership discussions, reducing Stockholm activities, and pursuing GMP certification for its Umeå biomanufacturing plant.
DIAGNODE-3 trial in HLA DR3-DQ2 genotype patients (40% of type 1 diabetes cases) was discontinued due to futility in preserving endogenous insulin production.
Announcement made public on April 23, 2026, at 11:
15 CET.